We provide you with 20 years of free, institutional-grade data for URGN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of URGN. Explore the full financial landscape of URGN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$465,114
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Schoenberg Mark | Sale | -871 | $19.11 | $16,645 | 2025-09-09 |
| Schoenberg Mark | Derivatives Exercise | 1,667 | 2025-09-09 | ||
| Smith Jason Drew | Sale | -1,520 | $19.11 | $29,047 | 2025-09-09 |
| Smith Jason Drew | Derivatives Exercise | 3,333 | 2025-09-09 | ||
| Schoenberg Mark | Sale | -10,000 | $17.69 | $176,900 | 2025-08-13 |
| Smith Jason Drew | Sale | -7,522 | $19.14 | $143,971 | 2025-07-30 |
| Smith Jason Drew | Derivatives Exercise | 16,500 | 2025-07-30 | ||
| Schoenberg Mark | Sale | -5,149 | $19.14 | $98,552 | 2025-07-30 |
| Schoenberg Mark | Derivatives Exercise | 10,000 | 2025-07-30 | ||
| Schoenberg Mark | Sale | -5,162 | $7.37 | $38,044 | 2025-06-11 |
| Schoenberg Mark | Derivatives Exercise | 10,000 | 2025-06-11 | ||
| Smith Jason Drew | Sale | -7,379 | $11.14 | $82,202 | 2025-02-04 |
| Smith Jason Drew | Derivatives Exercise | 14,667 | 2025-02-04 | ||
| Schoenberg Mark | Sale | -4,551 | $11.14 | $50,698 | 2025-02-04 |
| Schoenberg Mark | Derivatives Exercise | 8,000 | 2025-02-04 | ||
| Schoenberg Mark | Sale | -859 | $13.08 | $11,236 | 2024-09-12 |
| Schoenberg Mark | Derivatives Exercise | 1,666 | 2024-09-12 | ||
| Kim Dong | Derivatives Exercise | 2,500 | 2024-09-12 | ||
| Smith Jason Drew | Sale | -1,521 | $13.08 | $19,895 | 2024-09-12 |
| Smith Jason Drew | Derivatives Exercise | 3,333 | 2024-09-12 | ||
| Schoenberg Mark | Sale | -5,153 | $13.08 | $67,401 | 2024-06-11 |
| Schoenberg Mark | Derivatives Exercise | 10,000 | 2024-06-11 | ||
| Schoenberg Mark | Sale | -12,000 | $14.05 | $168,600 | 2024-03-20 |
| Kim Dong | Derivatives Exercise | 3,333 | 2024-02-12 | ||
| Schoenberg Mark | Sale | -3,789 | $15.78 | $59,790 | 2024-02-05 |
| Smith Jason Drew | Sale | -4,993 | $15.78 | $78,790 | 2024-02-05 |
| Schoenberg Mark | Sale | -3,789 | $15.74 | $59,639 | 2024-02-02 |
| Schoenberg Mark | Derivatives Exercise | 6,666 | 2024-02-02 | ||
| Kim Dong | Derivatives Exercise | 3,333 | 2024-02-02 | ||
| Smith Jason Drew | Sale | -4,993 | $15.74 | $78,590 | 2024-02-02 |
| Smith Jason Drew | Derivatives Exercise | 10,000 | 2024-02-02 | ||
| Smith Jason Drew | Sale | -3,800 | $18.01 | $68,438 | 2023-09-05 |
| Smith Jason Drew | Derivatives Exercise | 8,334 | 2023-09-05 | ||
| Cohen Fred E | Grant, award...etc | 69,339 | $9.54 | 2023-07-28 | |
| Nussbaum Ran | Derivatives Exercise | 3,241 | 2023-02-28 | ||
| Nussbaum Ran | Derivatives Exercise | 47,999 | 2023-02-28 | ||
| Barrett Elizabeth A. | Derivatives Exercise | 18,333 | 2023-02-02 | ||
| Schoenberg Mark | Sale | -1,900 | $10.12 | $19,228 | 2023-02-02 |
| Schoenberg Mark | Derivatives Exercise | 3,833 | 2023-02-02 | ||
| Smith Jason Drew | Sale | -1,636 | $10.12 | $16,556 | 2023-02-02 |
| Smith Jason Drew | Derivatives Exercise | 3,333 | 2023-02-02 | ||
| Schoenberg Mark | Derivatives Exercise | 122,677 | 2023-01-23 | ||
| Schoenberg Mark | Sale | -258 | $11.85 | $3,057 | 2022-11-02 |
| Schoenberg Mark | Derivatives Exercise | 500 | 2022-11-02 | ||
| Nussbaum Ran | Derivatives Exercise | 47,999 | 2022-10-25 | ||
| Belldegrun Arie | Derivatives Exercise | 160,000 | 2022-09-16 | ||
| Belldegrun Arie | Derivatives Exercise | 3,241 | 2022-09-02 | ||
| Smith Jason Drew | Sale | -3,606 | $7.21 | $25,999 | 2022-09-02 |
| Smith Jason Drew | Derivatives Exercise | 8,333 | 2022-09-02 | ||
| Schoenberg Mark | Sale | -259 | $7.81 | $2,023 | 2022-08-25 |
| Schoenberg Mark | Derivatives Exercise | 500 | 2022-08-25 | ||
| Nussbaum Ran | Derivatives Exercise | 1,030 | 2022-08-25 |
The information provided in this report about URGN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
UroGen Pharma Ltd(NASDAQ:URGN) 
UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmy...
Website: http://www.urogen.com
Founded: 2004
Full Time Employees: 187
Sector: Healthcare
Industry: Biotechnology